brintellex
ValprolBanner
Annals of Indian Academy of Neurology
  Users Online: 141 Home | About the Journal | InstructionsCurrent Issue | Back IssuesLogin      Print this page Email this page  Small font size Default font size Increase font size
 
ORIGINAL ARTICLE
Ahead of Print

The serum prolidase enzyme activity as a biomarker for evaluation of the subclinical vascular damage in children with epilepsy


1 Department of Pediatrics, Harran University School of Medicine, Sanliurfa, Turkey
2 Department of Pediatric Neurology, Harran University School of Medicine, Sanliurfa, Turkey
3 Department of Neurology, Harran University School of Medicine, Sanliurfa, Turkey
4 Department of Child and Adolescent Psychiatry, Celal Bayar University School of Medicine, Manisa, Turkey
5 Department of Pediatric Oncology, Harran University School of Medicine, Sanliurfa, Turkey

Correspondence Address:
Mustafa Çalik,
Department of Pediatric Neurology, Harran University School of Medicine, Osmanbey Campus, Sanliurfa
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/aian.AIAN_640_19

Backgroud: Epilepsy is a chronic medical condition requiring long term or even lifelong therapy. Various researches have shown that epilepsy patients have vascular risk factors such as abnormal lipids, insulin, elevated oxidative stress, chronic inflammation, and subclinical atherosclerosis. Objectives: The purpose of the present study was to determine serum prolidase enzyme activity as a biomarker in children taking antiepileptic drug treatment through comparison with control cases. Materials and Methods: The present study group consists of 61 children (20 females, 41 males) with epilepsy and a control group was formed of 32 healthy individuals (14 females, 18 males). Aspectrophotometric method was used to measure serum prolidase enzyme activity. Results: The epilepsy group demonstrated statistically significantly higher prolidase enzyme activity values when compared with the control group (P = 0.003). It was measured that the serum TOS and OSI values were significantly elevated in patients with epilepsy compared to controls (P < 0.001). However, serum TAS values were significantly lower in the epilepsy group than in the control group (P = 0.032). Conclusions: These results supported that epileptic patients taking the antiepileptic treatment had increased serum prolidase enzyme activity, suggesting that it may show an increased risk of subclinical vascular damage related to both chronic inflammation and fibrotic process associated with degenerated collagen turnover. Therefore, serum prolidase enzyme activity could be considered a useful biomarker for evaluation of the subclinical vascular damage in children with epilepsy on some antiepileptic drugs.


Print this article
 [NEXT]
 [PREV]
 Table of Contents

  Search Pubmed for
 
    -  Karacan N
    -  Çalik M
    -  Kazanasmaz H
    -  Ethemoğlu &
    -  Güzelçiçek A
    -  Yaşin S
    -  Kandemir H
    -  Çeçen E
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed106    
    PDF Downloaded14    

Recommend this journal